Bionomics (NASDAQ:BNOX) Receives Outperform Rating from William Blair

William Blair reiterated their outperform rating on shares of Bionomics (NASDAQ:BNOX) in a research note published on Friday morning,RTT News reports.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Bionomics in a report on Thursday, August 1st.

Bionomics Price Performance

BNOX stock opened at $0.29 on Friday. The firm has a 50 day moving average of $0.39 and a two-hundred day moving average of $0.63. Bionomics has a 12 month low of $0.18 and a 12 month high of $2.19.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC purchased a new stake in Bionomics Limited (NASDAQ:BNOX) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics as of its most recent SEC filing. 15.90% of the stock is currently owned by institutional investors.

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.